intraflagellar transport 57Genealiases: ESRRBL1 · HIPPI · MHS4R2 · OFD18
Q-omics provides the consensus-scored IFT57 profile across patient tissues and cancer cell-line models. IFT57 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IFT57 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, IFT57 protein abundance shows 20,723 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, KICH, and HNSC as cancer lineages where IFT57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFT57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFT57 survival associations across molecular data types. IFT57 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFT57 RNA expression–survival associations across cancer types. High IFT57 expression shows unfavorable associations in LGG, HNSC and KICH, but favorable associations in KIRC, LUAD and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IFT57 RNA expression.
This table summarizes IFT57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IFT57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFT57 shows lower tumor expression in KICH, THCA, LUSC and LUAD and higher tumor expression in HNSC and CHOL. The KICH box plot shows higher IFT57 RNA expression in normal versus tumor tissue (log2 FC = −2.177, t-test p < 0.001).
This table shows molecular features associated with IFT57 in patient tissues and cancer cell lines. In patient samples, IFT57 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, IFT57 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
